Ewha Biomedics Co.,Ltd. of Seoul at MEDICA 2022 in Düsseldorf -- COMPAMED Trade Fair
Manage stand orders
Select Option

Submit your contact details

Provide your contact details to the exhibitor. Optionally, you may also add a personal message.

Please log in

You must be logged in to send the contact request.

An error has occurred

Please check your internet connection or try again later.

Message has been sent

Your message to the exhibitor was sent successfully.

Company news

Date

Topic

14 Oct 2018

“Minimize patient pain” Developed the world's first ultra-precision drug injection device for subcutaneous injection

“Minimize patient pain” Developed the world's first ultra-precision drug injection device for subcutaneous injection

A domestic medical device company has developed a drug injection device that helps patients accurately administer drugs while reducing pain and discomfort when injecting anticancer drugs.

Ewha Biomedics, a company specializing in drug injection medical devices, announced on the 14th that it will launch the world's first “High Flow Anapa ’Anapa SC’. an ultra-precision drug injection device for subcutaneous injection.

Anapa SC is an automatic drug injection medical device aimed at precise administration of anticancer drugs for subcutaneous injection. It is a medical device that generates carbon dioxide gas that is harmless to the human body and injects drugs into the body at a constant rate using the pressure and pressure control device.

According to the company, it relieves the pain and discomfort of patients while subcutaneous injection of existing anticancer drugs. In addition, it improved the difficulty of injecting drugs and the risk of drug exposure during treatment of anticancer drugs by medical staff. Helps more accurately administer anticancer drugs. By injecting drugs regularly using a constant gas pressure, accurate automatic injection of drugs suitable to the anticancer drug dosing regimen is possible.

In addition, the patient's pain is reduced by injecting drugs at a constant rate. Since anticancer drugs are automatically injected, the loss of expensive anticancer drugs is minimized with a special design that minimizes residual drugs by medical staff.

The company said, “Recently, as a result of applying the subcutaneous injection of Herceptin, a breast cancer treatment, and Mabthera, a lymphoma treatment, through Samsung Seoul Hospital and Bucheon Soonchunhyang Hospital, The patient's satisfaction with pain relief  such as Reduction of pain during administration, reduction of swelling at the injection site, reduction of pain after administration, etc. was very high." In particular, it was found to be of great help in reducing the psychological burden of medical staff who had no choice but to face the complaints caused by the pain of patients.

More Less

01 Mar 2016

Successful Development of ‘ANAPA,’ First Gas-type Infusion Pump in the World

MOU between Ewha Bio-KAIST… Market Expansion to Southeast Asia·Europe
New 3rd Generation Infusion Pump … ‘Safety’ of Both Patient-Doctor Secured

Established as Ewha Yanghang in 1989, Ewha Biomedics (CEO Yonghyun Kim, to be called ‘Ewha’ from now) imported balloon-type portable infusion pumps for the first time in the nation, which brought pioneering discoveries to the treatment of acute·chronic pains.

In order to improve the shortcomings of the existing mechanical and balloon-type pumps, Ewha signed a MOU (memorandum of understanding) with KAIST (Korea Advanced Institute of Science and Technology). Ewha Biomedics is a professional medical device manufacturer that successfully developed ‘ANAPA,’ the first gas-type infusion pump in the world.

Based on continuous R&D and excellent technological skills, Ewha is growing fast to be competitive in global markets as well as in the domestic market. In particular, ANAPA is well reviewed as giving patients an opportunity for more accurate and safe pain relief and provides convenience to doctors who are the real users.

The value of Ewha products is well recognized, so Ewha is supplying its products to many university hospitals and general hospitals in the nation. Ewha obtained CE certification (Comunaute Europeenne Marking, which has to be awarded to sell products in Europe). It is also expanding to Southeast Asia and Europe to secure more diverse markets. It obtained various international certifications including ‘ISO 13485 quality management system.’

‘ANAPA’ is an innovative gas-generating infusion pump that holds solid material (Power Pill), the main ingredient of which is sodium carbonate, and liquid material, citric acid, in a container separated by a partition. When it is used, the partition will break and the chemical reaction between Power Pill and citrate will generate CO2. Then the pressure of CO2 will push the piston to inject the drug.

In the ‘KIMES 2016,’ Ewha will present various product lines following its motto, “ANAPA, innovative 3rd generation infusion pump, provides the most proper pain relief.’

According to Ewha, ANAPA was developed focusing on ‘accuracy’ among many functions that an infusion pump should have. It is because the medicine to be used for injection will be ‘narcotic/antipsychotic’ or a ‘high-risk drug,’ and the patient to be injected will have low immunity.

The principle of the injection pump is that the pressure of CO2 generated from the activation of sodium carbonate and citric acid will push forward the piston inside the injector.

The generated pressure will be kept to a certain level by various safety devices. The main safety device, ‘Relief Valve’ helps medicine to be distributed with the correct speed and amount for a certain period, since it can keep internal pressure steady by discharging the generated pressure inside the container into the air outside through the valve.

Also, a ‘Capillary’ controls the flow amount of the medicine once more to prevent the overdose. The infusion is confirmed by a 1 ml unit, so a patient or a doctor can check the drug injection accurately.

ANAPA has proven its excellent quality by winning a domestic patent and a utility model patent, which were given for its development of various features to improve the ‘user-friendliness’ for both patients and medical staff. One of the features is the ‘End Cap.’ which is designed to enable priming without opening a cap since the hydrophobic filter of the end cap allows the liquid to pass and block the gas.

Therefore, the product safety has improved as contamination is prevented by the exclusion of drug exposure during priming. The priming time is also reduced to three minutes, about 15 minutes shorter than other products, so the product can be used without delay.

ANAPA also provides new pain solutions that complement the limitations of existing infusion pumps.

◇Convenient ANAPA= a mechanical infusion pump has its disadvantages since it cannot be used widely due to the high cost and weight. Therefore, ANAPA is designed to have a reasonable price and it is light enough to be carried easily. Also, it comes with a pouch for convenient use and maintenance.

◇Accurate ANAPA= balloon-type infusion pumps, which are widely used these days, actually presented numerous problems relating to the flow amount in many cases. Moreover, there are no common guidelines, so each manufacturer uses a different standard when a measurement is made.

Also, any information on the difference in accuracy was not provided. Therefore, ANAPA offers infusion by a piston with a constant flow speed, so the drug will leave no remnant. Also, the accurate injection rate can be confirmed by the scale unit of 1 ml.

CEO Yonghyun Kim said, “ANAPA was named by an anesthesiologist who actually used the product. When pronounced as it is, ‘an apa’ means ‘no pain’ in Korean. This product contains a wishful thinking that prays for a world free from pain and the fast recovery of patients.”

More Less